# Walrinvax (bivalent HPV vaccine, Yuxi Zerun)

Source: https://onco.cc/drugs/walrinvax/  
OnCo record `walrinvax` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A bivalent HPV vaccine made in China by Yuxi Zerun Biotechnology, prequalified by WHO in August 2024.

## Summary

WHO's list of prequalified vaccines carries Walrinvax (Yuxi Zerun Biotechnology Co., Ltd, regulated by China's National Medical Products Administration) as a bivalent human papillomavirus vaccine in a single-dose vial, prequalified on 2 August 2024. It is the later of the two vaccines regulated by China's NMPA on the list, after Cecolin.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-11-04
- Tags: preventive-vaccine; hpv-vaccine
- Brand: Walrinvax
- Modality: Prophylactic vaccine (virus-like particles)
- Mechanism: Recombinant HPV L1 capsid proteins form virus-like particles that train the immune system to make antibodies against the HPV types the vaccine covers.
- Approvals: WHO 2024: WHO prequalification, bivalent HPV vaccine

## Sources

- WHO list of prequalified vaccines (CSV export): https://extranet.who.int/prequal/vaccines/prequalified/export?page&_format=csv

## Connected records

- drugs: [Cecolin (bivalent HPV vaccine, Xiamen Innovax)](https://onco.cc/drugs/cecolin/), [HPV bivalent vaccine (types 16 and 18)](https://onco.cc/drugs/hpv-bivalent-vaccine/)
- collections: [WHO list of prequalified vaccines](https://onco.cc/collections/who-prequalified-vaccines/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [HPV & HBV vaccination](https://onco.cc/technologies/hpv-vaccine/)
- pathways: [Oncogenic viruses](https://onco.cc/pathways/oncogenic-viruses/)

---
JSON: https://onco.cc/api/v1/entities/walrinvax.json